Download Files:
Products Details
Product Description
– Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure[1][2][3].
Web ID
– HY-A0230
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C22H30N2O5S2
References
– [1]Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66.|[2]Maul B, et al. Alcohol consumption is controlled by angiotensin II. FASEB J. 2001 Jul;15(9):1640-2.|[3]Olivetti G, et al. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993 Mar;21(3):362-70.
CAS Number
– 83647-97-6
Molecular Weight
– 466.61
SMILES
– CCOC([C@H](CCC1=CC=CC=C1)N[C@@H](C)C(N2CC3(SCCS3)C[C@H]2C(O)=O)=O)=O
Clinical Information
– Launched
Research Area
– Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– Angiotensin-converting Enzyme (ACE)
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
